| Theme | Up-to-date Treatment for Inflammatory Bowel Diseases | |
|---|---|---|
| Title | Infliximab (Remicade) for Treatment of Crohn's Disease | |
| Publish Date | 2008/05 | |
| Author | Hiroaki Ito | Kitano Hospital The Tazuke Kofukai Medical Research Institute, Digestive Health Center of Excellence |
| [ Summary ] | The anti-TNF-alpha monoclonal antibody infliximab (Remicade®) has dramatically changed therapeutic strategies for Crohn's disease. It has been shown that infliximab produces surprisingly high response and remission rates, has steroid-sparing effects, and displays strong evidence of mucosal healing which can decrease the need for hospitalization and surgery, thereby remarkably improving the quality of life for patients. It has also been proven that infliximab is much safer than steroids. It should be utilized to fully change the natural history of Crohn's disease. | |